+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The World Market for Liquid Biopsy, 2023

  • Report

  • 211 Pages
  • December 2022
  • Region: Global
  • Kalorama Information
  • ID: 5521308

Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report assesses the Liquid Biopsy Market now and in 2027.  The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.

Liquid biopsy is gaining acceptance each year.  Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies were conducted to assess the capability of these tests in clinical diagnostics uses.  While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

This report, The World Liquid Biopsy Market, 2023, contains up-to-date information and useful data points for business planning:

The Market for Liquid Biopsy by Region

  • North America
  • Europe
  • Asia
  • Rest of World

The Market for CTC-based Liquid Biopsy

  • Growth to 2027

The Market for ctDNA-based Liquid Biopsy

  • Growth to 2027

The Market for EV and Exosome-based Liquid Biopsy

  • Growth to 2027

The Market for Multi-Analyte-based Liquid Biopsy

  • Growth to 2027

The Market for Other Analytes Liquid Biopsy

  • Growth to 2027

Liquid Biopsy Market by Type of Cancer

  • Breast
  • Lung
  • Colorectal
  • Ovarian
  • Prostate
  • Pan-Cancer
  • Other Cancer

R&D: Selected ctDNA-based Liquid Biopsy Tests in Development

On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021

On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis/screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • These applications, increasing acceptance, the use of liquid biopsy in combination with other technologies. This report contains market assessments for these application categories.

In addition, the report profiles key companies in the market, including:

  • Adaptive Biotechnologies
  • Agena Bioscience, Inc.
  • Angle, PLC
  • Aspira Women’s Health
  • Biocartis Group Nv
  • Biocept, Inc.
  • Biodesix
  • Cellmax Life
  • Circulogene
  • Diacarta, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc. (Roche)
  • Freenome, Inc.
  • Gilupi Gmbh
  • Grail (Illumina)
  • Guardant Health, Inc.
  • Hologic
  • Lunglife AI (Formerly Cynvenio Biosystems)
  • Menarini-Silicon Biosystems, SPA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics Laboratories, Inc.
  • Oncocyte Corporation
  • Oncodna S.A.
  • Personal Genome Diagnostics
  • Qiagen N.V.
  • Cell-Free DNA Technologies
  • CTC Technologies
  • Exosome And Mirna Technologies
  • Resolution Biosciences (Agilent)
  • Roche Diagnostics
  • Sysmex-Inostics, Inc.
  • Tempus
  • Volitionrx

Table of Contents

Chapter One: Executive Summary
Introduction

Liquid Biopsy Technologies

Industry Structure

Liquid Biopsy Market Revenues and Forecast
  • Figure 1-1: Market for Liquid Biopsy 2022-2027
  • Figure 1-2: Global Liquid Biopsy Market by Geographic Region, 2022 (%)
  • Table 1-1:  Global Liquid Biopsy Market by Geographic Region, 2022-2027 $(M)
Chapter Two: Liquid Biopsy Technologies
Introduction
  • Table 2-1: Comparison of Tissue and Liquid Biopsy
Current Major Liquid Biopsy Technologies
  • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
Introduction

Advantages and Limitations of ctDNA in Liquid Biopsy

Current ctDNA-based Liquid Biopsy Tests
  • Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2022Company/ Country
Biocartis

Biocept

Biodesix

CellMax Life

Circulogene

Diacarta

Epigenomics

Foundation Medicine (Roche)

Guardant Health

Inivata (Neogenomics)

LungLife AI

Myriad Genetics

NeoGenomics

OncoDNA

Personal Genomic Diagnostics

QIAGEN

Resolution Biosciences

Roche Diagnostics

Sysmex-Inostics

Tempus

ctDNA-based Liquid Biopsy Tests in Development
  • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2022
Exact Sciences

Freenome

GRAIL

Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
Introduction

Challenges in the Development of CTC-based Liquid Biopsy Tests

CTC-based Liquid Biopsy Tests
  • Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2022
Adaptive Biotechnologies

ANGLE

Biocept

CellMax Life

Epic Sciences

GILUPI

LungLife AI

Menarini-Silicon Biosystems

QIAGEN

Selected CTC-based Liquid Biopsy Tests in Development
  • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2022
Epic Sciences

Liquid Biotech USA

Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
Introduction

Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
  • Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2022
Aspira Women’s Health (formerly Vermillion)

Biodesix

Exosome Diagnostics

Hologic

MDxHealth

Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
  • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2022
Circulogene

OncoCyte

Resolution Biosciences

VolitionRx

Chapter Six: Multi-Analyte Liquid Biopsy Tests
Introduction

Liquid Biopsy Tests Based on Multiple Analytes
  • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2022
Biocept

Biodesix

Foundation Medicine (Roche)

LungLife AI

NeoGenomics

OncoDNA

Multiple Analyte-based Liquid Biopsy Tests in Development
  • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2022
Exact Sciences

Freenome

GRAIL

LungLife AI

Chapter Seven: Liquid Biopsy Tests for Research Use Only
Introduction

Liquid Biopsy Tests for Research Use Only
  • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2022
Agena Bioscience

DiaCarta

Exosome Diagnostics

Guardant Health

Natera

QIAGEN

Chapter Eight: Liquid Biopsy Industry Analysis
Introduction

Tiers of Competition
  • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2022
Competitive Factors

Significant Market Trends
  • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2022
Personalized Medicine

Increasing Global Life Expectancy

New Liquid Biopsy Products

Increasing Accessibility of Genetic Testing

Regulatory Hurdles

Third-Party Payor Coverage

Demonstrated Clinical Utility

Incidence Rates of Specific Cancers

Competitors No Longer in the Liquid Biopsy Market
  • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
Market Overview
  • Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
  • Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2022 (%)
Market Forecast
  • Table 9-2: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2022-2027
Chapter Ten: Market by Analyte
Circulating Tumor DNA

Market Overview

Applications

Technologies

Specimens

Revenue Forecast
  • Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2022-2027
Circulating Tumor Cells

Market Overview

Applications

Technologies

Specimens

Revenue Forecast
  • Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2022-2027
Extracellular Vesicles and Other Analytes

Market Overview

Applications

Technologies

Specimens

Revenue Forecast
  • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2022-2027
Multiple Analytes

Market Overview

Revenue Forecast
  • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2022-2027
Chapter Eleven: Market by Application
Therapy Guidance and Monitoring

Market Overview

Revenue Forecast
  • Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2022-2027
Diagnosis/Screening

Market Overview

Revenue Forecast
  • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2022-2027
Disease Prognosis

Market Overview

Revenue Forecast
  • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2022-2027
Chapter Twelve: Market by Cancer Type
Breast Cancer

Market Overview

Revenue Forecast
  • Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2022-2027
Colorectal Cancer

Market Overview

Revenue Forecast
  • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2022-2027
Lung Cancer

Market Overview

Revenue Forecast
  • Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2022-2027
Ovarian Cancer

Market Overview

Revenue Forecast
  • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2022-2027
Prostate Cancer

Market Overview

Revenue Forecast
  • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2022-2027
Other Cancers

Market Overview

Revenue Forecast
  • Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2022-2027
Pan-Cancer Tests

Market Overview

Revenue Forecast
  • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2022-2027
Chapter Thirteen: Company Profiles
Companies in the Market
  • Table 13-1 Companies in the Liquid Biopsy Market
Adaptive Biotechnologies

Agena Bioscience, Inc.

ANGLE, plc

Aspira Women’s Health

Biocartis Group NV

Biocept, Inc.

Biodesix

CellMax Life

Circulogene

DiaCarta, Inc.

Epic Sciences

Epigenomics AG

Exact Sciences

Exosome Diagnostics, Inc.

Foundation Medicine, Inc. (Roche)

Freenome, Inc.

GILUPI GmbH

GRAIL (Illumina)

Guardant Health, Inc.

Hologic

LungLife AI (formerly Cynvenio Biosystems)

Menarini-Silicon Biosystems, Spa

Myriad Genetics, Inc.

Natera, Inc.

NeoGenomics Laboratories, Inc.

Oncocyte Corporation

OncoDNA S.A.

Personal Genome Diagnostics

QIAGEN N.V.

Cell-free DNA Technologies

CTC Technologies

Exosome and miRNA Technologies

Resolution Biosciences (Agilent)

Roche Diagnostics

Sysmex-Inostics, Inc.

Tempus

VolitionRx

Companies Mentioned

  • Adaptive Biotechnologies
  • Agena Bioscience, Inc.
  • Angle, Plc
  • Aspira Women’S Health
  • Biocartis Group Nv
  • Biocept, Inc.
  • Biodesix
  • Cellmax Life
  • Circulogene
  • Diacarta, Inc.
  • Epic Sciences
  • Epigenomics Ag
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc. (Roche)
  • Freenome, Inc.
  • Gilupi Gmbh
  • Grail (Illumina)
  • Guardant Health, Inc.
  • Hologic
  • Lunglife AI (Formerly Cynvenio Biosystems)
  • Menarini-Silicon Biosystems, Spa
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Neogenomics Laboratories, Inc.
  • Oncocyte Corporation
  • Oncodna S.A.
  • Personal Genome Diagnostics
  • Qiagen N.V.
  • Resolution Biosciences (Agilent)
  • Roche Diagnostics
  • Sysmex-Inostics, Inc.
  • Tempus
  • Volitionrx